Screener
Candel Therapeutics, Inc. CADL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | MARCH 31,2026(Unaudited) | DECEMBER 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $194,834 | $119,731 |
| Prepaid expenses and other current assets | 2,918 | 1,658 |
| Total current assets | 197,752 | 121,389 |
| Fixed assets, net | 2,075 | 1,642 |
| Lease right of use assets | 1,569 | 1,661 |
| Restricted cash | 416 | 416 |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s cash & equivalents?
- Candel Therapeutics, Inc. (CADL) reported cash & equivalents of $194.83M in Q1 2026.
- How has Candel Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Candel Therapeutics, Inc.'s cash & equivalents increased by 111.4% year-over-year, from $92.17M to $194.83M.
- What is the long-term trend for Candel Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s cash & equivalents has grown at a 27.8% compound annual growth rate (CAGR), from $35.05M to $119.73M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Candel Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude